Diasorin SpA (CHIX:DIAM) FCF Margin % : 22.68% (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Diasorin SpA FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Diasorin SpA's Free Cash Flow for the three months ended in Mar. 2025 was €71 Mil. Diasorin SpA's Revenue for the three months ended in Mar. 2025 was €313 Mil. Therefore, Diasorin SpA's FCF Margin % for the quarter that ended in Mar. 2025 was 22.68%.

As of today, Diasorin SpA's current FCF Yield % is 6.98%.

The historical rank and industry rank for Diasorin SpA's FCF Margin % or its related term are showing as below:

CHIX:DIAm' s FCF Margin % Range Over the Past 10 Years
Min: 17.28 Med: 21.92 Max: 29.32
Current: 29.32

During the past 13 years, the highest FCF Margin % of Diasorin SpA was 29.32%. The lowest was 17.28%. And the median was 21.92%.

CHIX:DIAm's FCF Margin % is ranked better than
95.67% of 208 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.155 vs CHIX:DIAm: 29.32

Diasorin SpA FCF Margin % Historical Data

The historical data trend for Diasorin SpA's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA FCF Margin % Chart

Diasorin SpA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

26.07

22.89

20.25

17.28

20.17

Diasorin SpA Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															25.95	26.62	45.64	23.52	22.68

Competitive Comparison of Diasorin SpA's FCF Margin %

For the Diagnostics & Research subindustry, Diasorin SpA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Diasorin SpA FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Diasorin SpA's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	239.066	/	1185.427
	=	20.17 %

Diasorin SpA's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	71	/	313
	=	22.68 %

Diasorin SpA FCF Margin % Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (CHIX:DIAm) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

DSRLF:USA DIA:Italy 0GZX:UK 34D:Germany DIAS:Austria

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines